Rtw Investments, LP Arbutus Biopharma Corp Transaction History

Rtw Investments, LP

$6.23 Billion
Q1 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $6.06 Million - $9.97 Million	-2,504,493 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $6.93 Million - $10.3 Million	-2,228,830 Reduced 47.09%	2,504,493 $9.74 Million
Q3 2021 Nov 15, 2021	SELL	$2.65 - $4.62 $3.3 Million - $5.75 Million	-1,245,032 Reduced 20.83%	4,733,323 $20.3 Million
Q3 2020 Nov 16, 2020	SELL	$1.75 - $6.2 $1.56 Million - $5.52 Million	-890,926 Reduced 12.97%	5,978,355 $18.7 Million
Q1 2020 May 15, 2020	BUY	$1.01 - $3.42 $1.21 Million - $4.11 Million	1,202,527 Added 21.22%	6,869,281 $6.94 Million

Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $90,294 - $299,944	103,787 Added 1.87%	5,666,754 $15.8 Million
Q3 2019 Nov 14, 2019	BUY	$1.34 - $2.4 $40,031 - $71,697	29,874 Added 0.54%	5,562,967 $8.48 Million
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $33,390 - $101,542	22,870 Added 0.42%	5,533,093 $11.5 Million
Q1 2019 May 15, 2019	BUY	$3.41 - $4.57 $4 Million - $5.37 Million	1,174,477 Added 27.09%	5,510,223 $19.7 Million
Q4 2018 Feb 14, 2019	BUY	$3.5 - $9.66 $877,947 - $2.42 Million	250,842 Added 6.14%	4,335,746 $16.6 Million
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $8.48 Million - $13.3 Million	-1,080,595 Reduced 20.92%	4,084,904 $38.6 Million
Q2 2018 Aug 14, 2018	BUY	$5.0 - $7.35 $69,420 - $102,047	13,884 Added 0.27%	5,165,499 $37.7 Million
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $510,259 - $882,920	-114,665 Reduced 2.18%	5,151,615 $26 Million
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $17.9 Million - $36.9 Million	5,266,280	5,266,280 $32.7 Million

Others Institutions Holding ABUS

# of Institutions

130

Shares Held

82.1M

Call Options Held

4.82M

Put Options Held

546K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $571M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.

Account